AstraZeneca plc (ADR) (AZN) was Upgraded by Liberum to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Liberum advised their investors in a research report released on Nov 25, 2016.
Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Initiated by Piper Jaffray to “Overweight” on Sep 23, 2016. AstraZeneca plc (ADR) was Upgraded by Jefferies to ” Buy” on Sep 12, 2016. AstraZeneca plc (ADR) was Upgraded by Argus to ” Buy” on Aug 29, 2016.
On the company’s financial health, AstraZeneca plc (ADR) reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.33 according to the earnings call on Nov 10, 2016. Analyst had a consensus of $0.99. The company had revenue of $5699.00 million for the quarter, compared to analysts expectations of $5939.86 million. The company’s revenue was down -2.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.03 EPS.
AstraZeneca plc (ADR) closed down -0.23 points or -0.84% at $27.12 with 69,94,277 shares getting traded on Monday. Post opening the session at $27.05, the shares hit an intraday low of $27 and an intraday high of $27.27 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).